A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
The purpose of this study is to characterize the treatment patterns associated with biologics
 agents use or non-biological therapy in participants with moderate to severe Ulcerative
 Colitis (UC) and Crohn's Disease (CD).
This is a non-interventional, retrospective and prospective study of participants with IBD.
 This study will collect data to provide accurate and comprehensive information related to
 treatment patterns associated with biologics use or non-biological therapy in participants
 with moderate to severe UC and CD in routine clinical practice.

 The study will have retrospective data collection from past records of participants within
 the last 2 years before participant's enrollment. The prospective part of the study will
 include one year of observation and data collection after the participant's enrollment in the
 study.

 The study will enroll approximately 2000 participants. Participants will be enrolled in one
 of the two groups:

 -  UC Participants

 -  CD Participants

 This multi-center trial will be conducted in Russia, Belarus and Kazakhstan. The overall
 period of observation in this study will be approximately 12 months. Participants will make 2
 visits within their routine practice to the clinic after the enrollment into the study
 including a final visit at Month 12.
Inclusion Criteria:

 1. Has confirmed diagnosis of CD or UC for at least 2 years prior to enrollment in the
 study.

 2. Has a moderate to severe IBD flare at the time of enrollment or in participant
 anamnesis within 2 years before enrollment treated with steroids or/ and
 immunosuppressive agents or/ and biologic therapy. IBD flare(s) must be confirmed in
 the source documentation.

 3. Current treatment with steroids or/ and immunosuppressive agents or/ and
 5-aminosalicylate (ASA) or/ and biologic therapy.

 Exclusion Criteria:

 1. Current or previous (within the last two years) indeterminate or not classified
 colitis.

 2. Changing of IBD type in anamnesis (that is, from UC to CD, etc) within the last two
 years.

 3. Current, previous (within the last two years) or planned (for the next one year)
 participation in interventional clinical trial.

 4. Presenting of mental incapacity, unwillingness or language barriers precluding
 adequate understanding or cooperation.

 5. Has received previous treatment with biologic therapy/immunosuppressive agents for
 conditions other than IBD ever in their lifetime.